Oral Rehydration Solution With Zinc and Prebiotics in Acute Diarrhea
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01025583 |
Recruitment Status :
Completed
First Posted : December 3, 2009
Last Update Posted : January 13, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diarrhea | Dietary Supplement: hypotonic oral rehydration solution Dietary Supplement: Hypotonic oral rehydration solution with Zn and prebiotics | Phase 2 Phase 3 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 130 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Efficacy of a New Hypotonic Oral Rehydration Solution Containing Zinc and Prebiotics in the Treatment of Children With Acute Diarrhea |
Study Start Date : | November 2007 |
Actual Primary Completion Date : | January 2008 |
Actual Study Completion Date : | March 2008 |
Arm | Intervention/treatment |
---|---|
Active Comparator: group 1 (standard ORS)
Children with acute diarrhea receive standard hypotonic ORS.
|
Dietary Supplement: hypotonic oral rehydration solution
30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
Other Name: REIDRAX |
Active Comparator: Group 2 (hypotonic super-ORS)
Children with acute diarrhea receive hypotonic super-ORS containing zinc and prebiotics.
|
Dietary Supplement: Hypotonic oral rehydration solution with Zn and prebiotics
30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
Other Name: PREREID |
- The primary outcome of the study is the rate of resolution of diarrhea 72 h after starting oral rehydration therapy. [ Time Frame: From November 2007 to January 2008 ]
- Secondary outcome measures are the total amount of ORS intake in the first 24 h, the number of missed work days of the parent, the number of hospital admissions in each group, and the use of other medications. [ Time Frame: From November 2007 to January 2008 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 3 Months to 36 Months (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Children 3-36 months old seen in the pediatrician offices presenting acute diarrhea lasting less than 48 h are considered eligible for the study
Exclusion Criteria:
- Diarrhea lasting more than 48 h
- Malnutrition as judged by a body weight/height ratio below the 5th percentile
- Clinical signs of severe dehydration
- Clinical signs of a coexisting severe acute systemic illness (meningitis, sepsis, pneumonia)
- Immunodeficiency
- Underlying severe chronic disease
- Malnutrition
- Cystic fibrosis
- Food allergy or other chronic gastrointestinal diseases
- Use of pre/probiotics in the previous 3 weeks
- Use of antibiotics or any antidiarrheal medication in the previous 3 weeks.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01025583
Italy | |
Pediatric Office | |
Naples, Italy, 80100 |
Principal Investigator: | Roberto Berni Canani, MD, PhD | Department of Pediatrics, University Federico II of Naples Italy |
Responsible Party: | Roberto Berni Canani, Department of Pediatrics University Federico II of Naples, Italy |
ClinicalTrials.gov Identifier: | NCT01025583 |
Other Study ID Numbers: |
184/08 01§/2008 ( Other Grant/Funding Number: Mother and Child Health Association ) |
First Posted: | December 3, 2009 Key Record Dates |
Last Update Posted: | January 13, 2010 |
Last Verified: | December 2009 |
acute gastroenteritis intestinal infection intestinal fluid secretion intestinal microflora treatment of childhood acute diarrhea |
Diarrhea Signs and Symptoms, Digestive Pharmaceutical Solutions |